ReviewHematology/oncology clinics of North America2014
Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.
Review in Hematology/oncology clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Activin Signaling Pathway Specialization During Embryonic and Skeletal Muscle Development in Rainbow Trout (Oncorhynchus mykiss).Marine biotechnology (New York, N.Y.) · 2024Article
- Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.Annals of hematology · 2021Article
- The Influence of Inflammation on Anemia in CKD Patients.International journal of molecular sciences · 2020Review
- Hepcidin agonists as therapeutic tools.Blood · 2018Review
- What can we learn from ineffective erythropoiesis in thalassemia?Blood reviews · 2018Review
- The Red Blood Cells on the Move!Frontiers in physiology · 2018Article
- How we manage iron overload in sickle cell patients.British journal of haematology · 2017Review
- β-Thalassemia.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Review
- The European Hematology Association Roadmap for European Hematology Research: a consensus document.Haematologica · 2016Article
- β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies.Haematologica · 2015Review
- Anemia: progress in molecular mechanisms and therapies.Nature medicine · 2015Review
- Iron age: novel targets for iron overload.Hematology. American Society of Hematology. Education Program · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Use of new compound such as inhibitors of JAK2 or transforming growth factor β-like molecules might soon revolutionize the treatment of β-thalassemia and related disorders. However, this situation requires careful optimization, noting the potential for off-target immune suppression for JAK2 inhibitors and the lack of mechanistic insights for the use of the ligand trap soluble molecules that sequester ligands of activin receptor IIA and B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.